Form 4: Kodiak Sciences Director Acquires Stock Options

Kodiak Sciences Inc. reports that Director Bassil Dahiyat acquired stock options, with vesting contingent on continued service.

Summary

• Bassil Dahiyat, a Director at Kodiak Sciences Inc. (KOD), has acquired stock options.
• The transaction date for the earliest transaction is June 30, 2026.
• The acquired options represent the right to buy common stock at an exercise price of $38.96 per share.
• A total of 17,731 stock options were granted.
• These options are set to expire on June 29, 2036.
• Vesting terms indicate that 100% of the shares subject to the option will vest upon the earlier of June 30, 2027, or one day prior to the Issuer's next annual meeting after the grant date.
• Continued service as a member of the Issuer's board of directors through the applicable vesting date is a condition for vesting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard grant of stock options to a director, which is a common compensation practice and does not inherently signal positive or negative performance.

Positives

• Director Bassil Dahiyat's acquisition of stock options signals continued commitment and potential future value appreciation for the company.
• The vesting schedule, tied to continued service, aligns management's interests with the company's long-term performance.
• The exercise price of $38.96 suggests a belief in the stock's potential to trade above this level.

Negatives

• The filing is a standard Form 4 reporting a grant of options, not a sale of stock, so there are no immediate negative financial implications from this specific transaction.
• The vesting is contingent on continued service, meaning the options could be forfeited if the director steps down before the vesting dates.

Risks

• The primary risk is that the director may not continue to serve on the board, leading to forfeiture of the unvested options.
• The value of the options is subject to market fluctuations and the company's future performance, meaning they could expire worthless if the stock price does not exceed the exercise price.

Future Outlook

The future outlook for the acquired options depends on the company's stock performance and the reporting person's continued service. The options are exercisable until June 29, 2036, with full vesting potentially occurring by June 30, 2027, provided the director remains on the board.

Management Comments

• "One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date."

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, including companies like Kodiak Sciences, to incentivize long-term commitment and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The grant of options does not immediately dilute share count but represents potential future dilution if exercised. It also signals management's confidence in future stock performance.
• Employees: This type of compensation for directors is standard and does not directly impact employees.
• Creditors: No direct impact on creditors.
• Suppliers: No direct impact on suppliers.

Next Steps

• The reporting person may exercise the vested options if the stock price is favorable.
• The company will continue to monitor the director's service to ensure vesting conditions are met.

Key Dates

Keywords

Kodiak Sciences, KOD, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Insider Trading, Vesting Schedule